Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DORA: Durvalumab and Olaparib in mTNBC
NCT03167619Phase 2Completed
- Sponsor
- Duke University
- Start
- Oct 2018
- Primary completion
- Jun 2021
- Modality
- Antibody Conjugates, Small Molecules, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, olaparib in triple-negative breast cancer (TNBC), sponsored by Duke University. Started Oct 2018; status: completed.
02
Drugs
durvalumabolaparib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03167619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03167619.